HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

RC529

structure in first source

Also Known As:

RC 529; RC-529; Ribi 529; Ribi-529; Ribi529

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Evans, Jay T: 2 articles (12/2005 - 01/2002)
2.	Ward, Jon R: 2 articles (12/2005 - 01/2002)
3.	Chilton, Paula M: 1 article (12/2005)
4.	Mitchell, Thomas C: 1 article (12/2005)
5.	Thompson, Bruce S: 1 article (12/2005)
6.	Baldridge, Jory R: 1 article (01/2002)
7.	Brookshire, Valerie G: 1 article (01/2002)
8.	Cluff, Christopher W: 1 article (01/2002)
9.	Johnson, David A: 1 article (01/2002)
10.	Lacy, Michael J: 1 article (01/2002)

Related Diseases

1.	Human Influenza (Influenza) 01/01/2002 - "Intranasal administration of RC-524 or RC-529 to mice 2 days prior to a lethal influenza challenge provided significant protection in each case. "
2.	Inflammation (Inflammations) 12/01/2005 - "Our results indicate that low-inflammation adjuvants, such as MPL and RC529, are capable of enhancing short-term CD4+ T cell clonal expansion and Th1 differentiation, but inflammatory signaling aids in the long-term retention of antigen-specific T cells."
3.	Acquired Immunodeficiency Syndrome (AIDS) 12/01/2005 - "Our results indicate that low-inflammation adjuvants, such as MPL and RC529, are capable of enhancing short-term CD4+ T cell clonal expansion and Th1 differentiation, but inflammatory signaling aids in the long-term retention of antigen-specific T cells."

Related Drugs and Biologics

1.	Antigens
2.	RC524

Related Therapies and Procedures

1.	Intranasal Administration